FDA approval a milestone in the prevention of motion sickness
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in… Read More